735 results match your criteria CNS Melanoma


From putative brain tumor marker to high cognitive abilities: emerging roles of a disintegrin and metalloprotease (ADAM) 12 in the brain.

J Chem Neuroanat 2020 Jul 2:101846. Epub 2020 Jul 2.

Department of Psychiatry, Otto-von-Guericke University, Magdeburg, Germany.

ADAM (a disintergin and metalloprotease) 12 is a member of the large family of multidomain metalloprotease-disintegrins, which possess cell-binding and metalloprotease properties. The enzyme is responsible for the shedding of a number of membrane-bound proteins (heparin-binding-EGF, insulin-like growth factor 2-binding proteins 3 and 5, oxytocinase, glycoprotein non-metastatic melanoma protein B and basigin). In rat and human CNS, ADAM12 is predominantly localized in white and gray matter oligodendrocytes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jchemneu.2020.101846DOI Listing

In vivo effects of the association of the psychoactive phenotiazine thioridazine on antitumor activity and hind limb paralysis induced by the native polypeptide crotamine.

Toxicon 2020 Jul 1. Epub 2020 Jul 1.

Departamento de Farmacologia, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), SP, Brazil. Electronic address:

Crotamine is a cationic polypeptide composed by 42 amino acid residues with several pharmacological and biological properties, including the selective ability to enter and kill actively proliferating tumour cells, which led us to propose its use as a theranostic agent for cancer therapy. At the moment, the improvement of crotamine antitumoral efficacy by association with chemotherapeutic adjuvants is envisioned. In the present work, we evaluated the association of crotamine with the antitumoral adjuvant phenotiazine thioridazine (THD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.toxicon.2020.06.017DOI Listing

Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient.

Immunotherapy 2020 Jun 22. Epub 2020 Jun 22.

Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Leptomeningeal disease (LMD) from melanoma is rapidly fatal with median overall survival between 6.9 weeks and 3.5 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2019-0004DOI Listing

Characteristics of melanoma in the elderly.

Rev Col Bras Cir 2020 15;47:e20202441. Epub 2020 Jun 15.

Hospital Erasto Gaertner, Serviço de Pele e Melanoma - Curitiba - PR - Brasil.

Objective: This study evaluates melanoma characteristics in the elderly.

Methods: A retrospective descriptive analytical study was carried out by reviewing the medical records of patients aged 60 years or older, diagnosed with primary cutaneous melanoma, and treated at Hospital Erasto Gaertner, Curitiba, Paraná, from 2013 to 2017.

Results: We studied 139 patients aged 60-98 years (average, 70. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/0100-6991e-20202441DOI Listing

Evaluation of Innate Immune Mediators Related to Respiratory Viruses in the Lung of Stable COPD Patients.

J Clin Med 2020 Jun 10;9(6). Epub 2020 Jun 10.

Divisione di Pneumologia e Laboratorio di Citoimmunopatologia dell'Apparato Cardio Respiratorio, Istituti Clinici Scientifici Maugeri SpA, Società Benefit, IRCCS, Veruno, Via Revislate 13, 28010 Novara, Italy.

Little is known about the innate immune response to viral infections in stable Chronic Obstructive Pulmonary Disease (COPD). Objectives: To evaluate the innate immune mediators related to respiratory viruses in the bronchial biopsies and lung parenchyma of stable COPD patients. We evaluated the immunohistochemical (IHC) expression of Toll-like receptors 3-7-8-9 (TLR-3-7-8-9), TIR domain-containing adaptor inducing IFNβ (TRIF), Interferon regulatory factor 3 (IRF3), Phospho interferon regulatory factor 3  ( pIRF3), Interferon regulatory factor 7 (IRF7), Phospho interferon regulatory factor 7 (pIRF7), retinoic acid-inducible gene I (RIG1), melanoma differentiation-associated protein 5 (MDA5), Probable ATP-dependent RNA helicase DHX58 ( LGP2), Mitochondrial antiviral-signaling protein (MAVS), Stimulator of interferon genes (STING), DNA-dependent activator of IFN regulatory factors (DAI), forkhead box protein A3(FOXA3), Interferon alfa (IFNα), and Interferon beta (IFNβ) in the bronchial mucosa of patients with mild/moderate ( = 16), severe/very severe ( = 18) stable COPD, control smokers (CS) ( = 12), and control non-smokers (CNS) ( = 12). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm9061807DOI Listing

Increasing incidence of cancer and stage migration towards advanced disease in children and young adolescents in the Netherlands, 1990-2017.

Eur J Cancer 2020 Jul 7;134:115-126. Epub 2020 Jun 7.

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. Electronic address:

Background: This is the first national study on trends in cancer incidence for children and young adolescents in the Netherlands, including stage at diagnosis as a potential marker of early diagnosis and better staging.

Methods: All neoplasms in patients younger than 18 years, diagnosed between 1990 and 2017 (N = 15,233), were derived from the Netherlands Cancer Registry. Incidence rates and the average annual percentage change with 95% CIs were calculated for all cancers combined and diagnostic (sub)groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2020.04.011DOI Listing

Advances in Management of Brain and Leptomeningeal Metastases.

Curr Neurol Neurosci Rep 2020 Jun 6;20(7):26. Epub 2020 Jun 6.

Center for Neuro-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

Purpose Of Review: The management of brain and leptomeningeal metastases has changed significantly over the past decade.

Recent Findings: Historically, radiation therapy had been the mainstay of treatment. Several strategies to limit toxicities with radiation have been developed in the recent years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11910-020-01039-1DOI Listing

Biomarkers for immunotherapy for treatment of glioblastoma.

J Immunother Cancer 2020 May;8(1)

National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA

Immunotherapy is a promising new therapeutic field that has demonstrated significant benefits in many solid-tumor malignancies, such as metastatic melanoma and non-small cell lung cancer. However, only a subset of these patients responds to treatment. Glioblastoma (GBM) is the most common malignant primary brain tumor with a poor prognosis of 14. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jitc-2019-000348DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264836PMC

Rho GTPases in Gynecologic Cancers: In-Depth Analysis toward the Paradigm Change from Reactive to Predictive, Preventive, and Personalized Medical Approach Benefiting the Patient and Healthcare.

Cancers (Basel) 2020 May 20;12(5). Epub 2020 May 20.

Predictive, Preventive and Personalised (3P) Medicine, Department of Radiation Oncology, University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, 53113 Bonn, Germany.

Rho guanosine triphospatases (GTPases) resemble a conserved family of GTP-binding proteins regulating actin cytoskeleton dynamics and several signaling pathways central for the cell. Rho GTPases create a so-called Ras-superfamily of GTPases subdivided into subgroups comprising at least 20 members. Rho GTPases play a key regulatory role in gene expression, cell cycle control and proliferation, epithelial cell polarity, cell migration, survival, and apoptosis, among others. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12051292DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281750PMC

Immunotherapy for Medulloblastoma: Current Perspectives.

Immunotargets Ther 2020 20;9:57-77. Epub 2020 Apr 20.

Department of Internal Medicine-Medical Oncology, Markey Cancer Center, University of Kentucky, Lexington, KY, USA.

Background: Immune-mediated therapies have transformed the treatment of metastatic melanoma and renal, bladder, and both small and non-small cell lung carcinomas. However, immunotherapy is yet to demonstrate dramatic results in brain tumors like medulloblastoma for a variety of reasons. Recent pre-clinical and early phase human trials provide encouraging results that may overcome the challenges of central nervous system (CNS) tumors, which include the intrinsic immunosuppressive properties of these cancers, a lack of antigen targets, antigenic variability, and the immune-restrictive site of the CNS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/ITT.S198162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182450PMC

Vaccines adjuvanted with an NKT cell agonist induce effective T-cell responses in models of CNS lymphoma.

Immunotherapy 2020 Apr 22;12(6):395-406. Epub 2020 Apr 22.

Malaghan Institute of Medical Research, P.O. Box 7060, Wellington 6242, New Zealand.

The efficacy of anti-lymphoma vaccines that exploit the cellular adjuvant properties of activated natural killer T (NKT) cells were examined in mouse models of CNS lymphoma. Vaccines were prepared by either loading the NKT cell agonist, α-galactosylceramide onto irradiated and heat-shocked B- and T-lymphoma cells, or chemically conjugating α-galactosylceramide to MHC-binding peptides from a lymphoma-associated antigen. Vaccine efficacy was analyzed in mice bearing intracranial tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2019-0134DOI Listing

Central nervous system complications associated with immune checkpoint inhibitors.

J Neurol Neurosurg Psychiatry 2020 07 20;91(7):772-778. Epub 2020 Apr 20.

Centre National de Référence pour les Syndromes Neurologiques Paranéoplasiques, Hospices Civils de Lyon, Lyon, France

Objective: To describe the spectrum and outcome of central nervous system complications associated with immune checkpoint inhibitors (CNS-ICI).

Methods: Patients with CNS-ICI were identified and their characteristics compared with ICI-related peripheral neuropathy (PN-ICI).

Results: We identified 19 patients with CNS-ICI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jnnp-2020-323055DOI Listing

Immunotherapy for Neuro-Oncology.

Adv Exp Med Biol 2020 ;1244:183-203

Department of Neuro-Oncology, MD Anderson Cancer Center, Houston, TX, USA.

Immunotherapy has changed the landscape of treatment of many solid and hematological malignancies and is at the forefront of cancer breakthroughs. Several circumstances unique to the central nervous system (CNS) such as limited space for an inflammatory response, difficulties with repeated sampling, corticosteroid use for management of cerebral edema, and immunosuppressive mechanisms within the tumor and brain parenchyma have posed challenges in clinical development of immunotherapy for intracranial tumors. Nonetheless, the success of immunotherapy in brain metastases (BMs) from solid cancers such as melanoma and non-small cell lung cancer (NSCLC) proves that the CNS is not an immune-privileged organ and is capable of initiating and regulating immune responses that lead to tumor control. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-030-41008-7_8DOI Listing

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.

Lancet Oncol 2020 05 3;21(5):655-663. Epub 2020 Apr 3.

Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, CT, USA.

Background: We did a phase 2 trial of pembrolizumab in patients with non-small-cell lung cancer (NSCLC) or melanoma with untreated brain metastases to determine the activity of PD-1 blockade in the CNS. Interim results were previously published, and we now report an updated analysis of the full NSCLC cohort.

Methods: This was an open-label, phase 2 study of patients from the Yale Cancer Center (CT, USA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(20)30111-XDOI Listing

Synthesis, biological evaluation and virtual screening of some acridone derivatives as potential anticancer agents.

Bioorg Med Chem 2020 May 19;28(9):115426. Epub 2020 Mar 19.

Department of Chemistry, Tennessee State University, 3500 John A. Merritt Blvd., Nashville, TN 37209-1561, United States. Electronic address:

Eleven novel acridone derivatives were synthesized and evaluated for their anticancer activity against 60 human cancer cell lines. Five compounds 8b, 8d, 8g, 8h, and 8k displayed very good in vitro antiproliferative activities well over 95% of the panels. The most active compound is 8k (5, 7-dibromo-3-phenyl-3,4-dihydroacridin-1 (2H)-one). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2020.115426DOI Listing

Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.

Lancet Oncol 2020 04 17;21(4):541-550. Epub 2020 Mar 17.

Department of Pediatrics, Division of Hematology and Oncology, Stanford University, Stanford, CA, USA. Electronic address:

Background: Immune checkpoint inhibitors targeting PD-1 have shown clinical benefit in adults with cancer, but data on these drugs in children are scarce. We did a phase 1-2 study of nivolumab, a PD-1 blocking monoclonal antibody, to determine its safety, pharmacokinetics, and antitumour activity in children and young adults with recurrent or refractory non-CNS solid tumours or lymphoma.

Methods: We did a multicentre, open-label, single-arm, dose-confirmation and dose-expansion, phase 1-2 trial in 23 hospitals in the USA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(20)30023-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255545PMC

Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer.

Onco Targets Ther 2020 23;13:667-683. Epub 2020 Jan 23.

Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu 610041, People's Republic of China.

The central nervous system (CNS) is regarded as an immune privileged environment; however, changes in the neuroimmunology paradigm have led to an increased interest in systematic immunotherapy in lung cancer therapy. The presence of the lymphatic system in the CNS as well as the physiological and biochemical changes in the blood-brain barrier in the tumor microenvironment suggests that immunocytes are fully capable of entering and exiting the CNS. Emerging clinical data suggest that inhibitors of programmed death receptor-1/programmed death ligand 1 (PD-1/PD-L1) can stimulate surrounding T cells and thus have antitumor effects in the CNS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S235714DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986404PMC
January 2020

Metastases to the central nervous system: Molecular basis and clinical considerations.

J Neurol Sci 2020 May 21;412:116755. Epub 2020 Feb 21.

Department of Neurology, Poznan University of Medical Sciences, Poland.

Background: Metastatic tumors are the most common malignancies of the central nervous system (CNS) in adults. CNS metastases are associated with unfavorable prognosis, high morbidity and mortality. Lung cancer is the most common source of brain metastases, followed by breast cancer and melanoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2020.116755DOI Listing

Potential 2,4-dimethyl-1H-pyrrole-3-carboxamide bearing benzimidazole template: Design, synthesis, in vitro anticancer and in silico ADME study.

Bioorg Chem 2020 Apr 11;97:103660. Epub 2020 Feb 11.

Deparment of Chemistry, Baburaoji Gholap College, Affiliated to Savitribai Phule Pune University, Sangvi, Pune 411017, India. Electronic address:

A new series of 2,4-dimethyl-1H-pyrrole-3-carboxamide derivatives bearing benzimidazole moiety was synthesized through a molecular hybridization approach and evaluated for in vitro anticancer activity by NCI-60 on leukemia, melanoma, lung, colon, CNS, ovarian, renal, prostate and breast cancer cell lines at a single dose (10 µM). Among all the synthesized conjugates, some derivatives showed more or less good activity even at such a small dose, while, compound 5-(1H-benzo[d]imidazol-2-yl)-N-(1-cyclohexylethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (8f) displayed significant antiproliferative activity specifically against MDA-MB human cancer cell lines. Compound 8f showed promising activity against MDA-MB-435 cell line of melanoma (Growth inhibition: 62. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bioorg.2020.103660DOI Listing

Pediatric primary diffuse leptomeningeal melanomatosis: Case report and review of the literature.

Medicine (Baltimore) 2020 Feb;99(8):e19178

Department of Neurosurgery.

Rationale: Primary melanocytic tumors of central nerve system (CNS) are rare, primary diffuse leptomeningeal melanomatosis (PDLM), a subtype of malignant melanomas of CNS, is extremely rare,especially in pediatrics. As the clinical manifestation of PDLM is not characteristic, It is often misdiagnosed as tubercular meningitis and hemorrhage.

Patient Concerns: A 13-year-old boy was admitted to our department with symptoms of recurrent headache and vomiting twice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000019178DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034675PMC
February 2020

CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.

Oncologist 2020 Feb 18;25(2):112-118. Epub 2019 Oct 18.

Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.

Combined MEK-BRAF inhibition is a well-established treatment strategy in BRAF-mutated cancer, most prominently in malignant melanoma with durable responses being achieved through this targeted therapy. However, a subset of patients face primary unresponsiveness despite presence of the activating mutation at position V600E, and others acquire resistance under treatment. Underlying resistance mechanisms are largely unknown, and diagnostic tests to predict tumor response to BRAF-MEK inhibitor treatment are unavailable. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2019-0356DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011664PMC
February 2020
4.865 Impact Factor

Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma.

J Clin Oncol 2020 May 28;38(13):1429-1441. Epub 2020 Jan 28.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

Purpose: Improved understanding of the incidence, risk factors, and timing of CNS metastasis is needed to inform surveillance strategies for patients with melanoma.

Patients And Methods: Clinical data were extracted from the databases of 2 major melanoma centers in the United States and Australia for 1,918 patients with American Joint Committee on Cancer (AJCC) 8th edition stage III melanoma, diagnosed from 1998-2014, who had (negative) baseline CNS imaging within 4 months of diagnosis. The cumulative incidence of CNS metastasis was calculated in the presence of the competing risk of death, from stage III presentation and at benchmark time points 1, 2, and 5 years postdiagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.01508DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193747PMC

Extracranial systemic antitumor response through the abscopal effect induced by brain radiation in a patient with metastatic melanoma.

Radiat Oncol J 2019 12 31;37(4):302-308. Epub 2019 Dec 31.

University Cancer and Diagnostic Centers, Houston, TX, USA.

The abscopal effect is a term that has been used to describe the phenomenon in which localized radiation therapy treatment of a tumor lesion triggers a spontaneous regression of metastatic lesion(s) at a non-irradiated distant site(s). Radiation therapy induced abscopal effects are believed to be mediated by activation and stimulation of the immune system. However, due to the brain's distinctive immune microenvironment, extracranial abscopal responses following cranial radiation therapy have rarely been reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3857/roj.2019.00437DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952716PMC
December 2019

Evaluating S100B as a serum biomarker for central neurosarcoidosis.

Respir Med 2020 02 21;162:105855. Epub 2019 Dec 21.

Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA.

Background: S100B is a calcium-binding protein found primarily in glial cells. In the setting of neuronal injury and disruption of the blood brain barrier, S100B can leak into the cerebrospinal fluid and systemic circulation.

Objectives: To determine if serum S100B distinguishes patients with central neurosarcoidosis (NS) from patients with extra-neurologic sarcoidosis (ENS) and healthy controls, and if S100B levels correlate with MRI measures of disease burden. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2019.105855DOI Listing
February 2020

Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management.

Melanoma Manag 2019 Nov 8;6(4):MMT30. Epub 2019 Nov 8.

Unit of Melanoma, Cancer Immunotherapy & Innovative Therapies Unit - Istituto Nazionale Tumori Fondazione 'G. Pascale,' IRCCS, 80131, Napoli, Italy.

Checkpoint inhibitors can cause an imbalance in immune tolerance that may clinically manifest as immune-related adverse events (irAEs). These events may involve many organs and tissues, including the skin, gastrointestinal (GI) tract, liver, endocrine system, kidneys, central nervous system (CNS), eyes and lungs. The incidence of irAEs appears to be lower with anti-programmed death antigen-1/programmed death antigen-ligand-1 agents than with the anti-cytotoxic T-lymphocyte-associated protein-4 antibody ipilimumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt-2019-0005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920742PMC
November 2019

The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.

J Neurooncol 2020 Jan 14;146(1):181-193. Epub 2019 Dec 14.

Centre Hospitalier Universitaire Vaudois (CHUV), Oncology Service, Precision Oncology Center, Oncology Department, Rue du Bugnon 46, CH-1011, Lausanne, Switzerland.

Background: Evidence pointing to a synergistic effect of stereotactic radiosurgery (SRS) with concurrent immunotherapy or targeted therapy in patients with melanoma brain metastases (BM) is increasing. We aimed to analyze the effect on overall survival (OS) of immune checkpoint inhibitors (ICI) or BRAF/MEK inhibitors initiated during the 9 weeks before or after SRS. We also evaluated the prognostic value of patients' and disease characteristics as predictors of OS in patients treated with SRS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-019-03363-0DOI Listing
January 2020

EV71 Infection Induces IFNβ Expression in Neural Cells.

Viruses 2019 12 4;11(12). Epub 2019 Dec 4.

Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Kwei-Shan, Tao-Yuan 33303, Taiwan.

Enterovirus 71 (EV71) can invade the central nervous system (CNS) and cause neurological disease. Accumulating evidence indicates that EV71 can directly infect neurons in the CNS. Innate immune responses in the CNS have been known to play an essential role in limiting pathogen infections. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/v11121121DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6950376PMC
December 2019

Reprofiling of pyrimidine-based DAPK1/CSF1R dual inhibitors: identification of 2,5-diamino-4-pyrimidinol derivatives as novel potential anticancer lead compounds.

J Enzyme Inhib Med Chem 2020 Dec;35(1):311-324

Chemical Kinomics Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.

Hybridization of reported weakly active antiproliferative hit 5-amino-4-pyrimidinol derivative with 2-anilino-4-phenoxypyrimidines suggests a series of 2,5-diamino-4-pyrimidinol derivatives as potential antiproliferative agents. Few compounds belonging to the proposed series were reported as CSF1R/DAPK1 inhibitors as anti-tauopathies. However, the correlation between CSF1R/DAPK1 signalling pathways and cancer progression provides motives to reprofile them against cancer therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14756366.2019.1699554DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913669PMC
December 2020

Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient.

J Immunother Cancer 2019 12 2;7(1):336. Epub 2019 Dec 2.

Department of Medical Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.

Background: Immune checkpoint inhibitors (ICPis) have revolutionised the treatment of melanoma by significantly increasing survival rates and disease control. However, ICPis can have specific immune-related adverse events, including rare but severe neurological toxicity.

Case Presentation: We report a 44-year-old man diagnosed with stage IIIB melanoma who developed metastatic disease (pulmonary and brain metastases) and was treated with stereotactic radiosurgery and nivolumab immunotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0818-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889661PMC
December 2019

The Tumor Suppressor Role of Zinc Finger Protein 671 () in Multiple Tumors Based on Cancer Single-Cell Sequencing.

Front Oncol 2019 8;9:1214. Epub 2019 Nov 8.

Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.

In humans, zinc finger protein 671 () is a type of transcription factor. However, the contribution of tumor heterogeneity to the functional role of remains unknown. The present study aimed to determine the functional states of in cancer single cells based on single-cell sequencing datasets (scRNA-seq). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.01214DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857622PMC
November 2019

Type I interferon (IFN)-inducible Absent in Melanoma 2 proteins in neuroinflammation: implications for Alzheimer's disease.

Authors:
Divaker Choubey

J Neuroinflammation 2019 Nov 26;16(1):236. Epub 2019 Nov 26.

Department of Environmental Health, University of Cincinnati, 160 Panzeca Way, P. O. Box 670056, Cincinnati, OH, 45267, USA.

Cumulative evidence indicates that activation of innate immune responses in the central nervous system (CNS) induces the expression of type 1 interferons (T1 IFNs), a family of cytokines. The T1 IFNs (IFN-α/β), through activation of the JAK/STAT-signaling in microglia, astrocytes, and neurons, induce the expression of IFN-inducible proteins, which mediate the pro- and anti-inflammatory functions of IFNs. Accordingly, T1 IFN-inducible Absent in Melanoma 2 proteins (murine Aim2 and human AIM2) negatively regulate the expression of TI IFNs and, upon sensing higher levels of cytosolic DNA, assemble the Aim2/AIM2 inflammasome, resulting in activation of caspase-1, pyroptosis, and the secretion of pro-inflammatory cytokines (e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12974-019-1639-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880379PMC
November 2019
5.408 Impact Factor

Cancer Incidence and Mortality in Firefighters: A State-of-the-Art Review and Meta-َAnalysis.

Asian Pac J Cancer Prev 2019 Nov 1;20(11):3221-3231. Epub 2019 Nov 1.

Harvard T.H. Chan School of Public Health, Department of Environmental Health, Environmental and Occupational Medicine and Epidemiology (EOME), Boston, MA, USA.

Objective: A systematic literature review and meta-analysis was conducted on the association between firefighting and cancer.

Methods: A comprehensive literature search of databases including Medline, EMBASE, Biosis, NIOSHTIC2, Web of Science, Cancerlit, and HealthStar, for the period between 1966 to January 2007, was conducted. We also retrieved additional studies by manual searching. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.31557/APJCP.2019.20.11.3221DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063017PMC
November 2019

Metastatic Disease to Clivus: Biopsy or Not?

Cureus 2019 Sep 14;11(9):e5658. Epub 2019 Sep 14.

Neurosurgery, Desert Regional Medical Center, Palm Springs, USA.

Due to the aggressive nature of hepatocellular carcinoma (HCC), most patients succumb to disease before any distant metastasis, such as to the central nervous system (CNS), can occur. Thus only a handful of cases of metastasis to the skull base have been described. After a thorough review of the available literature published since 1950, we report the sixth case of HCC metastasis to the clivus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.5658DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823025PMC
September 2019

Brain Metastases as a First Site of Recurrence in Patients Receiving Chemotherapy with Controlled Systemic Cancer: a Critical but Under-Recognized Clinical Scenario.

Curr Treat Options Neurol 2019 Nov 9;21(11):55. Epub 2019 Nov 9.

The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital, 401 N. Broadway, Baltimore, MD, 21287, USA.

Purpose Of Review: As the treatment of many malignancies has improved, brain metastases (BM) have been observed as a site of the first recurrence in patients with controlled systemic cancers. This suggests that while the administered chemotherapy is effective against systemic cancer, drug concentrations in the central nervous system (CNS) are likely too low to be effective. These findings are in accord with data suggesting that more than 98% of FDA-approved drugs on the market today are unable to cross the blood-brain barrier (BBB). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11940-019-0598-6DOI Listing
November 2019
4 Reads

Factors Impacting Fertility Preservation in Adolescents and Young Adults with Cancer: A Retrospective Study.

J Adolesc Young Adult Oncol 2020 Apr 25;9(2):208-221. Epub 2019 Oct 25.

Department of Pediatrics, Hematology Oncology, University of Iowa Hospitals and Clinics, Stead Family Children's Hospital, Iowa City, Iowa.

Fertility preservation before therapy is underutilized for those diagnosed with cancer as an adolescent or young adult (AYA). The purpose of this study was to describe factors impacting utilization of fertility preservation consultations and procedures among AYAs at the University of Iowa Health Care (UIHC). Patients were identified by the oncology registry at UIHC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jayao.2019.0100DOI Listing

Leptomeningeal metastases arising from gynecological cancers.

Int J Clin Oncol 2020 Feb 4;25(2):391-395. Epub 2019 Oct 4.

Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi, Hyogo, 673-8558, Japan.

Background: Most cases of leptomeningeal metastasis (LM) arise from solid tumors, such as breast cancer, lung cancer, or malignant melanoma. LM arising from gynecological cancers are extremely rare. Longer survival owing to recent advances in chemotherapy and other treatments has contributed to the increased frequency of gynecological cancers metastasizing to the central nervous system (CNS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-019-01556-1DOI Listing
February 2020
1 Read

Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172).

Eur J Cancer 2019 11 30;121:144-153. Epub 2019 Sep 30.

Department of Medical Oncology, Mount Vernon Cancer Centre, London, United Kingdom.

Background: Limited data are available on nivolumab in challenging subgroups with advanced melanoma. We report outcomes of nivolumab after prior ipilimumab in patients who are typically excluded from clinical trials.

Patients And Methods: In this phase II, single-arm, open-label, multicentre study (CheckMate 172), patients with advanced melanoma who progressed on or after ipilimumab received nivolumab 3 mg/kg, every 2 weeks for up to 2 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.08.014DOI Listing
November 2019
7 Reads

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.

J Transl Med 2019 09 5;17(1):303. Epub 2019 Sep 5.

Department of Medical Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090, Brussels, Belgium.

Background: Treatment with anti-PD1 monoclonal antibodies improves the survival of metastatic melanoma patients but only a subgroup of patients benefits from durable disease control. Predictive biomarkers for durable benefit could improve the clinical management of patients.

Methods: Plasma samples were collected from patients receiving anti-PD1 therapy for ctDNA quantitative assessment of BRAF and NRAS mutations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-019-2051-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727487PMC
September 2019
2 Reads

Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma.

Cancer 2019 Dec 9;125(23):4193-4202. Epub 2019 Aug 9.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Background: Melanoma brain metastases (MBM) occur in up to 50% of patients with metastatic melanoma (MM) and represent a frequent site of systemic treatment failure for targeted therapies. However, to the authors' knowledge, little is known regarding the incidence, patterns of disease progression, and outcomes of MBM in patients treated with anti-PD-1 immunotherapy.

Methods: A total of 320 patients with MM who were treated with anti-PD-1 at The University of Texas MD Anderson Cancer Center in Houston were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32454DOI Listing
December 2019
4 Reads
4.889 Impact Factor

Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma.

J Immunother Cancer 2019 07 24;7(1):196. Epub 2019 Jul 24.

Section of Surgical Oncology, Yale School of Medicine, 20 Park Street, New Haven, CT, 06519, USA.

Background: Checkpoint inhibitors (CPI) have revolutionized the treatment of metastatic melanoma, but most patients treated with CPI eventually develop progressive disease. Local therapy including surgery, ablation or stereotactic body radiotherapy (SBRT) may be useful to manage limited progression, but criteria for patient selection have not been established. Previous work has suggested progression-free survival (PFS) after local therapy is associated with patterns of immunotherapy failure, but this has not been studied in patients treated with CPI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0672-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657062PMC
July 2019
3 Reads

Primary Malignant Melanoma of the Brain: A Population-Based Study.

World Neurosurg 2019 Oct 16;130:e1091-e1097. Epub 2019 Jul 16.

Department of Neurosurgery, University of Illinois at Chicago, Chicago, Illinois, USA. Electronic address:

Background: Primary melanocytic neoplasms of the central nervous system (CNS) are rare and account for 1% of all melanomas. This study used the Surveillance, Epidemiology, and End Results (SEER) database to evaluate the epidemiology of primary CNS melanoma and further characterize their treatment.

Methods: Data from the National Cancer Institute SEER program, collected from 1973-2015, were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2019.07.095DOI Listing
October 2019
3 Reads

Substrate Reduction Therapy for Sandhoff Disease through Inhibition of Glucosylceramide Synthase Activity.

Mol Ther 2019 08 4;27(8):1495-1506. Epub 2019 Jun 4.

Sanofi, 49 New York Avenue, Framingham, MA 01701, USA. Electronic address:

Neuronopathic glycosphingolipidoses are a sub-group of lysosomal storage disorders for which there are presently no effective therapies. Here, we evaluated the potential of substrate reduction therapy (SRT) using an inhibitor of glucosylceramide synthase (GCS) to decrease the synthesis of glucosylceramide (GL1) and related glycosphingolipids. The substrates that accumulate in Sandhoff disease (e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ymthe.2019.05.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697407PMC
August 2019
32 Reads
6.227 Impact Factor

Familial aggregation of early-onset cancers.

Int J Cancer 2020 04 27;146(7):1791-1799. Epub 2019 Jun 27.

Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland.

This registry-linkage study evaluates familial aggregation of cancer among relatives of a population-based series of early-onset (≤40 years) cancer patients in Finland. A cohort of 376,762 relatives of early-onset cancer patients diagnosed between 1970 and 2012 in 40,538 families was identified. Familial aggregation of early-onset breast, colorectal, brain and other central nervous system (CNS) cancer and melanoma was explored by standardized incidence ratios (SIR), stratified by relatedness. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32512DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027840PMC
April 2020
16 Reads

Synthesis and biological evaluation of indole-2-carbohydrazides and thiazolidinyl-indole-2-carboxamides as potent tubulin polymerization inhibitors.

Comput Biol Chem 2019 Jun 11;80:512-523. Epub 2019 May 11.

Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Istanbul University, Istanbul, Turkey; Faculty of Pharmacy, Istanbul Yeni Yuzyil University, Istanbul, Turkey. Electronic address:

A new series of N'-(substituted phenyl)-5-chloro/iodo-3-phenyl-1H-indole-2-carbohydrazide (5, 6) and N-[2-(substituted phenyl)-4-oxo-1,3-thiazolidin-3-yl]-5-iodo/chloro-3-phenyl-1H-indole-2-carboxamide (7, 8) derivatives were synthesized and evaluated for their anticancer properties. Compounds 5a and 6b, selected as prototypes by the National Cancer Institute for screening against the full panel of 60 human tumor cell lines at a minimum of five concentrations at 10-fold dilutions, demonstrated remarkable antiproliferative activity against leukemia, non-small cell lung cancer, colon cancer, central nervous system (CNS) cancer, melanoma, ovarian cancer, renal cancer, and breast cancer (MCF-7) cell lines with GI values < 0.4 μM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.compbiolchem.2019.05.002DOI Listing
June 2019
16 Reads

Diagnostic dilemma of ocular lymphoma.

BMJ Case Rep 2019 Jun 6;12(6). Epub 2019 Jun 6.

Singleton Hospital, Swansea, UK.

We report a very unusual presentation of primary intraocular lymphoma masquerading as anterior uveitis with atypical symptoms. A 68-year-old man, initially presented with a 4-day history of painless, left blurred vision. Examination revealed 2 or more anterior chamber cells, mutton-fat keratic precipitates and posterior synechiae. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2019-229513DOI Listing
June 2019
16 Reads

Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review.

BMC Cancer 2019 May 30;19(1):519. Epub 2019 May 30.

Department of Neuro-oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.

Background: Recently, two phase II trials showed intracranial activity of the immune checkpoint inhibitors nivolumab and ipilimumab in patients with melanoma brain metastases. However, it is generally assumed that large molecules like monoclonal antibodies nivolumab and ipilimumab cannot penetrate and pass an intact blood brain barrier (BBB). In this systematic review we provide a pharmacodynamic and pharmacokinetic consideration of the clinical activity of the immune checkpoint inhibitors nivolumab and ipilimumab in melanoma brain metastases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5741-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543612PMC
May 2019
6 Reads

Modern Management of Central Nervous System Metastases in the Era of Targeted Therapy and Immune Oncology.

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:e59-e69. Epub 2019 May 17.

4 Department of Thoracic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.

Metastases to the central nervous system (CNS) are associated with considerable morbidity and mortality in patients with cancer. Historically, very few systemic therapies have shown efficacy in this patient population. Emerging data are now demonstrating that whole-brain radiation therapy, previously considered the mainstay of treatment of brain metastases, is associated with high rates of neurotoxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_241345DOI Listing
January 2019
5 Reads

Targeted Therapies for Brain Metastases.

Prog Neurol Surg 2019 16;34:125-137. Epub 2019 May 16.

Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.

The most common primary cancers that metastasize to the brain are lung cancer, breast cancer, and melanoma. The established management approaches for brain metastasis include stereotactic radiosurgery, fractionated radiation therapy, and surgical resection. In the past the role of medical therapies in brain metastases was limited. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/493057
Publisher Site
http://dx.doi.org/10.1159/000493057DOI Listing
December 2019
18 Reads